Alumis Inc. reported financial results for the year ended December 31, 2025, with total revenue of $24.1 million, R&D expenses of $386.0 million, G&A expenses of $91.9 million, and net loss of $243.3 million. Highlights include positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis and $308.5 million in cash position.
Key takeaways
Positive Phase 3 ONWARD1 and ONWARD2 topline results for envudeucitinib in moderate-to-severe plaque psoriasis, meeting all primary and secondary endpoints with ~65% PASI 90 and >40% PASI 100 at Week 24.
Plan to submit NDA for envudeucitinib in psoriasis in 2H 2026.
Potentially pivotal Phase 2b topline data for envudeucitinib in SLE anticipated 3Q 2026.
Completed upsized public offering of 20,297,500 shares at $17.00 per share, raising $345.1 million gross proceeds in Jan 2026.
Cash, cash equivalents and marketable securities of $308.5 million as of December 31, 2025.
Cash expected to fund operating expenses and capital expenditures into Q4 2027.